Trial Profile
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alteplase (Primary) ; Aspirin
- Indications Stroke
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PRISMS
- Sponsors Genentech
- 21 Feb 2020 Primary endpoint has not been met. (3-month EQ5D scores)
- 21 Feb 2020 Results of post hoc analysis testing the hypothesis that the presence of infarction at 24h would independently predict worse outcome at 3 months, and also exploring the role of final infarct volume (FIV) on outcomes, presented at the International Stroke Conference 2020
- 10 Jul 2018 Results published in the JAMA: the Journal of the American Medical Association.